|
🐜
|
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
12 auth.
M. Ellis,
A. Coop,
Baljit Singh,
L. Mauriac,
Antonio Llombert-Cussac,
F. Jänicke,
...
W. Miller,
D. Evans,
M. Dugan,
C. Brady,
E. Quebe‐Fehling,
M. Borgs
|
10 |
2001 |
10
🐜
|
|
🐢
|
A standard curve based method for relative real time PCR data processing
A. Larionov,
Andreas Krause,
W. Miller
|
9 |
2005 |
9
🐢
|
|
🐬
|
Concentrations of parabens in human breast tumours
P. Darbre,
A. Aljarrah,
W. Miller,
N. Coldham,
M. Sauer,
G. S. Pope
|
9 |
2004 |
9
🐬
|
|
🐜
|
Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
12 auth.
M. Ellis,
Y. Tao,
Jingqin R Luo,
R. A’Hern,
D. Evans,
A. Bhatnagar,
...
Hilary A. Chaudri Ross,
Alexander von Kameke,
W. Miller,
I. Smith,
W. Eiermann,
M. Dowsett
|
9 |
2008 |
9
🐜
|
|
🐜
|
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
88 auth.
S. Eccles,
E. Aboagye,
Simak Ali,
A. Anderson,
J. Armes,
F. Berditchevski,
J. Blaydes,
K. Brennan,
N. Brown,
H. Bryant,
N. Bundred,
J. Burchell,
A. Campbell,
J. Carroll,
R. Clarke,
...
C. Coles,
G. Cook,
A. Cox,
N. Curtin,
L. Dekker,
I. Dos,
Santos Silva,
S. Duffy,
D. Easton,
D. Eccles,
D. Edwards,
J. Edwards,
G. Evans,
D. Fenlon,
J. Flanagan,
C. Foster,
W. Gallagher,
M. García-Closas,
J. Gee,
A. Gescher,
V. Goh,
A. Groves,
A. Harvey,
M. Harvie,
B. Hennessy,
S. Hiscox,
I. Holen,
S. Howell,
A. Howell,
G. Hubbard,
N. Hulbert-Williams,
M. Hunter,
B. Jasani,
L. Jones,
T. Key,
C. Kirwan,
A. Kong,
I. Kunkler,
S. Langdon,
M. Leach,
D. Mann,
J. Marshall,
L. Martin,
Stewart G. Martin,
J. Macdougall,
D. Miles,
W. Miller,
Joanna R. Morris,
S. Moss,
P. Mullan,
R. Natrajan,
J. O. Connor,
R. O. Connor,
C. Palmieri,
P. Pharoah,
E. Rakha,
E. Reed,
S. Robinson,
E. Sahai,
J. Saxton,
P. Schmid,
M. Smalley,
V. Speirs,
R. Stein,
J. Stingl,
C. Streuli,
A. Tutt,
G. Velikova,
R. Walker,
C. Watson,
K. Williams,
L. Young,
A. Thompson
|
8 |
2013 |
8
🐜
|
|
🐜
|
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
20 auth.
M. Kaufmann,
G. Minckwitz,
H. Bear,
H. Bear,
A. Buzdar,
P. Mcgale,
H. Bonnefoi,
M. Colleoni,
C. Denkert,
W. Eiermann,
...
R. Jackesz,
A. Makris,
W. Miller,
J. Pierga,
V. Semiglazov,
A. Schneeweiss,
R. Souchon,
V. Stearns,
M. Untch,
S. Loibl
|
8 |
2007 |
8
🐜
|
|
🦁
|
The importance of local synthesis of estrogen within the breast
W. Miller,
J. O'Neill
|
8 |
1987 |
8
🦁
|
|
🐜
|
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
19 auth.
T. Miller,
J. Balko,
Emily M. Fox,
Z. Ghazoui,
A. Dunbier,
H. Anderson,
M. Dowsett,
Aixiang Jiang,
R. A. Smith,
S. Maira,
...
H. Manning,
A. González-Angulo,
G. Mills,
C. Higham,
S. Chanthaphaychith,
M. Kuba,
W. Miller,
Y. Shyr,
C. Arteaga
|
7 |
2011 |
7
🐜
|
|
🐢
|
Aromatase activity in adipose tissue from breast quadrants: a link with tumour site
J. O'Neill,
R. Elton,
W. Miller
|
7 |
1988 |
7
🐢
|
|
🐢
|
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
11 auth.
M. Ellis,
A. Coop,
Baljit Singh,
Y. Tao,
A. Llombart-Cussac,
F. Jänicke,
...
L. Mauriac,
E. Quebe‐Fehling,
H. Chaudri-Ross,
D. Evans,
W. Miller
|
7 |
2003 |
7
🐢
|
|
🦁
|
Significance of aromatase activity in human breast cancer.
W. Miller,
R. Hawkins,
A. Forrest
|
7 |
1982 |
7
🦁
|
|
🦁
|
Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer.
W. Miller
|
7 |
2003 |
7
🦁
|
